Abstract

Ovarian cancer is a significant challenge among female reproductive system malignancies. The hyper activation of the phosphatidylinositol-3-kinase/protein kinase B signaling pathway is common in cancer and regulates cellular processes like proliferation and survival. The objective of this study was to investigate danshensu’s regulatory effects on the phosphatidylinositol-3-kinase/protein kinase B pathway in ovarian cancer. Danshensu-treated ovarian cancer cells were compared to control groups using immunoblotting. The danshensu-treated group showed significantly reduced protein expression levels of phosphatidylinositol-3-kinase, protein kinase B, and phospho-protein kinase B compared to the control group. Particularly, danshensu treatment led to notably lower expression levels of phosphatidylinositol-3-kinase and protein kinase B, as well as altered phospho-protein kinase B expression. This indicates that danshensu may inhibit the phosphatidylinositol- 3-kinase/protein kinase B pathway, impacting ovarian cancer cell survival and proliferation by reducing phosphatidylinositol-3-kinase and protein kinase B activity. As a result, danshensu holds promise as a potential therapeutic agent for ovarian cancer by regulating the phosphatidylinositol- 3-kinase/protein kinase B signaling pathway, but further in vivo research is necessary to confirm its effectiveness and safety and to elucidate specific mechanisms of action. Danshensu presents new opportunities for personalized ovarian cancer treatment.